Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study

View ORCID ProfileNaïm Ouldali, Haleh Bagheri, Francesco Salvo, Denise Antona, Antoine Pariente, Claire Leblanc, Martine Tebacher, Joëlle Micallef, Corinne Levy, Robert Cohen, Etienne Javouhey, Brigitte Bader-Meunier, Caroline Ovaert, Sylvain Renolleau, Veronique Hentgen, Isabelle Kone-Paut, Nina Deschamps, Loïc De Pontual, Xavier Iriart, Christelle Gras-Le Guen, François Angoulvant, View ORCID ProfileAlexandre Belot, the “French Covid-19 Paediatric Inflammation Consortium”, the “French Pharmacovigilance network”
doi: https://doi.org/10.1101/2022.01.17.22269263
Naïm Ouldali
1Assistance Publique-Hôpitaux de Paris, Department of general paediatrics, paediatric infectious disease and internal medicine, Robert Debré university hospital, Université de Paris, Paris, France
2Infectious Diseases Division, CHU Sainte Justine - Montreal University, Montreal, Quebec, Canada
3ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
4Université de Paris, INSERM UMR 1123, ECEVE, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Naïm Ouldali
  • For correspondence: naim.ouldali@aphp.fr alexandre.belot@chu-lyon.fr
Haleh Bagheri
5Department of Medical and Clinical Pharmacology, Regional Pharmacovigilance Center, CIC 1436, Toulouse University Hospital, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Salvo
6INSERM, BPH, U1219, Team Pharmacoepidemiology, Université de Bordeaux, 33000 Bordeaux, France
7Pole de Santé Publique, Service de Pharmacologie Médicale, Regional pharmacovigilance center of Bordeaux, CHU de Bordeaux, 33000 Bordeaux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise Antona
8Santé Publique France, Agence nationale de Santé publique, Saint-Maurice, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Pariente
9Team Pharmacoepidemiology, Bordeaux University, INSERM, U1219 BPH Research Center, Bordeaux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Leblanc
1Assistance Publique-Hôpitaux de Paris, Department of general paediatrics, paediatric infectious disease and internal medicine, Robert Debré university hospital, Université de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine Tebacher
10Regional pharmacovigilance center of Strasbourg, HUS, Strasbourg, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joëlle Micallef
11Marseille University hospital, Clinical pharmacology department Regional Pharmacovigilance Center of Marseille, France
12Aix-Marseille University, INSERM UMR 1106, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corinne Levy
3ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
13Centre Hospitalier Intercommunal, Research Center, Université Paris Est, IMRB-GRC GEMINI, Créteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Cohen
3ACTIV, Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil, France
13Centre Hospitalier Intercommunal, Research Center, Université Paris Est, IMRB-GRC GEMINI, Créteil, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etienne Javouhey
14Hospices Civils de Lyon, Paediatric Intensive Care Unit, Hopital Femme, Mère Enfant, University of Lyon, Bron, France
15EA 7426 “Pathophysiology of Injury-Induced Immunosuppression”, University Claude Bernard Lyon 1, Hospices Civils of Lyon, Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigitte Bader-Meunier
16Department of Paediatric Hematology-Immunology and Rheumatology, Necker-Enfants Malades Hospital, AP-HP, Paris, France, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France
17Laboratory of Immunogenetics of Paediatric Autoimmunity, Imagine Institute, Inserm U 1163, Paris University, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Ovaert
18Department of Pediatric Cardiology, Hôpital Timone Enfant, AP-HM, Marseille, France
19Aix-Marseille University, MMG, INSERM, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvain Renolleau
20Pediatric Intensive Care Unit, Necker Hospital, AP-HP, Paris University, Paris, France
21Paris University, EA7323, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronique Hentgen
22General Pediatrics department, Versailles Hospital, Paris, France
23CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Kone-Paut
23CEREMAIA (French reference center for auto-inflammatory diseases and inflammatory amyloidosis), Paris, France
24Pediatric Rheumatology Department, Bicêtre Hospital, APHP, University of Paris Saclay, Kremlin Bicêtre, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Deschamps
25General Pediatrics department, Saint-Malo Hospital, Saint-Malo, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loïc De Pontual
26General Pediatrics and Pediatric emergency department, Jean Verdier Hospital, Bondy, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier Iriart
27Department of Pediatric and Adult Congenital Cardiology, Bordeaux University Hospital, Pessac, France
28Institut Hospitalo-Universitaire Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, Pessac, Bordeaux, France
29INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, Bordeaux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christelle Gras-Le Guen
30Department of Pediatric Emergency Care, Nantes University Hospital, F-44000, Nantes, France
31Obstetrical, Perinatal and Pediatric Epidemiology Research team, Center of Research in Epidemiology and Statistics, Université de Paris, INSERM, F-75004, Paris, France
32Inserm CIC 1413, Nantes University Hospital, F-44000, Nantes, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Angoulvant
1Assistance Publique-Hôpitaux de Paris, Department of general paediatrics, paediatric infectious disease and internal medicine, Robert Debré university hospital, Université de Paris, Paris, France
33INSERM, Centre de Recherche des Cordeliers, UMRS 1138, Sorbonne Université, Université de Paris, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandre Belot
34Hospices Civils de Lyon, Paediatric Nephrology, Rheumatology, Dermatology, Hopital Femme, Mère Enfant, & Centre International de Recherche en Infectiologie / INSERM U1111, Bron, France
35National Reference Center for Rheumatic and AutoImmune and Systemic Diseases in Children (RAISE), Lyon, France
36International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, 69007 Lyon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexandre Belot
  • For correspondence: naim.ouldali@aphp.fr alexandre.belot@chu-lyon.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Multisystem inflammatory syndrome in children (MIS-C) is the most severe life-threatening clinical entity associated with pediatric SARS-CoV-2 infection. Whether COVID-19 mRNA vaccine can induce this complication in children is unknown.

Objective To assess the risk of hyper-inflammatory syndrome following COVID-19 mRNA vaccine in children.

Design, Setting, and Participants Post-authorization national population-based surveillance using the French enhanced pharmacovigilance surveillance system for COVID-19 vaccines. All cases of suspected hyper-inflammatory syndrome following COVID-19 mRNA vaccine in 12– 17-year-old children between June 15th, 2021 and January 1st, 2022, were reported. Each case was assessed for WHO MIS-C criteria. Causality assessment followed 2019 WHO recommendations.

Exposure COVID-19 mRNA vaccine.

Main Outcome and Measures The main outcome was the reporting rate of post-vaccine hyper-inflammatory syndrome per 1,000,000 COVID-19 mRNA vaccine doses in 12–17-year-old children. This reporting rate was compared to the MIS-C rate per 1,000,000 12–17-year-old children infected by SARS-CoV-2. Secondary outcomes included the comparison of clinical features between post-vaccine hyper-inflammatory syndrome and post SARS-CoV-2 MIS-C.

Results From June 2021 to January 2022, 8,113,058 COVID-19 mRNA vaccine doses were administered to 4,079,234 12–17-year-old children. Among them, 9 presented a multisystemic hyper-inflammatory syndrome. All cases fulfilled MIS-C WHO criteria. Main clinical features included male predominance (8/9, 89%), cardiac involvement (8/9, 89%), digestive symptoms (7/9, 78%), coagulopathy (5/9, 54%), cytolytic hepatitis (4/9, 46%), and shock (3/9, 33%). 3/9 (33%) required intensive care unit transfer, and 2/9 (22%) hemodynamic support. All cases recovered. Only three cases had evidence of previous SARS-CoV-2 infection. The reporting rate was 1.1 (95%CI [0.5; 2.1]) per 1,000,000 doses injected. As a comparison, 113 MIS-C (95%CI [95; 135]) occurred per 1,000,000 12–17-year-old children infected by SARS-CoV-2. Clinical features (inflammatory parameters, cytopenia) slightly differed from post-SARS-CoV-2 MIS-C, along with short-term outcomes (less PICU transfer than MIS-C).

Conclusion and Relevance Very few cases of hyper-inflammatory syndromes with multi-organ involvement occurred following COVID-19 mRNA vaccine in 12–17-year-old children. The low reporting rate of this syndrome, compared to the rate of MIS-C among same age children infected by SARS-CoV-2, supports the benefit of SARS-CoV-2 vaccination in children. Further studies are required to explore specific pathways of this entity compared to post-SARS-CoV-2 MIS-C.

Question Is COVID-19 mRNA vaccine in 12-17-year-old children associated with subsequent multisystemic hyper-inflammatory syndrome?

Findings The French national pharmacovigilance system identified 9 children with a hyper-inflammatory syndrome with multi-organ involvement following COVID-19 mRNA vaccination (reporting rate 1.1 [0.5; 2.1] per 1,000,000 doses), of which only three had evidence of previous SARS-CoV-2 infection. All cases fulfilled WHO definition for MIS-C, but clinical and immunological features, along with short-term outcomes, slightly differed from classical post SARS-CoV-2 MIS-C.

Meaning Very rare cases of hyper-inflammatory syndrome can occur following COVID-19 mRNA vaccine in 12-17-year-old children. The very low rate of this entity, compared to classical post-SARS-CoV-2 MIS-C, supports the benefit of SARS-CoV-2 vaccination in children.

Competing Interest Statement

NO reports travel grants from GSK, Pfizer, and Sanofi. Dr Javouhey reported receiving grants from CSL Behring. Dr C. Levy reported receiving grants from GlaxoSmithKline, Merck Sharp & Dohme, and Sanofi and personal fees from Pfizer and Merck. Dr Cohen reported receiving personal fees from GlaxoSmithKline, Pfizer, Sanofi, and Merck Sharp & Dohme. All other authors have no potential conflicts of interest to disclose.

Funding Statement

NO was supported by the 2021 ESPID (European Society for Pediatric Infectious Diseases) Fellowship Award. the French Covid-19 Paediatric Inflammation Consortium received an unrestricted grant from the Square Foundation (Grandir Fonds de Solidarity Pour L enfance).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the French INSERM ethics committee for evaluation (IRB00003888). A written information form validated by the ethics committee was given to all participants. Oral consent was obtained from study participants; no family members or participants refused to participate.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵£ Complete lists of members of the “French Covid-19 Paediatric Inflammation Consortium” are provided in the acknowledgment section

  • ↵* Complete lists of members of the “French Pharmacovigilance network” are provided in the acknowledgment section.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 18, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study
Naïm Ouldali, Haleh Bagheri, Francesco Salvo, Denise Antona, Antoine Pariente, Claire Leblanc, Martine Tebacher, Joëlle Micallef, Corinne Levy, Robert Cohen, Etienne Javouhey, Brigitte Bader-Meunier, Caroline Ovaert, Sylvain Renolleau, Veronique Hentgen, Isabelle Kone-Paut, Nina Deschamps, Loïc De Pontual, Xavier Iriart, Christelle Gras-Le Guen, François Angoulvant, Alexandre Belot, the “French Covid-19 Paediatric Inflammation Consortium”, the “French Pharmacovigilance network”
medRxiv 2022.01.17.22269263; doi: https://doi.org/10.1101/2022.01.17.22269263
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study
Naïm Ouldali, Haleh Bagheri, Francesco Salvo, Denise Antona, Antoine Pariente, Claire Leblanc, Martine Tebacher, Joëlle Micallef, Corinne Levy, Robert Cohen, Etienne Javouhey, Brigitte Bader-Meunier, Caroline Ovaert, Sylvain Renolleau, Veronique Hentgen, Isabelle Kone-Paut, Nina Deschamps, Loïc De Pontual, Xavier Iriart, Christelle Gras-Le Guen, François Angoulvant, Alexandre Belot, the “French Covid-19 Paediatric Inflammation Consortium”, the “French Pharmacovigilance network”
medRxiv 2022.01.17.22269263; doi: https://doi.org/10.1101/2022.01.17.22269263

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pediatrics
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (506)
  • Anesthesia (110)
  • Cardiovascular Medicine (1244)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (532)
  • Epidemiology (10027)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2462)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1645)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (250)
  • HIV/AIDS (535)
  • Infectious Diseases (except HIV/AIDS) (11871)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (253)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2289)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1248)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (325)
  • Pediatrics (733)
  • Pharmacology and Therapeutics (314)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2281)
  • Public and Global Health (4840)
  • Radiology and Imaging (838)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (286)
  • Sexual and Reproductive Health (240)
  • Sports Medicine (227)
  • Surgery (268)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)